Engineered oncolytic virus coated with anti-PD-1 and alendronate for ameliorating intratumoral T cell hypofunction
This approach effectively improved the immunosuppressive microenvironment of glioblastoma and achieved a robust anti-tumor effect. Consequently, this study presents a novel strategy for immune combination therapy and the improvement of the glioblastoma immune microenvironment, thereby offering new prospects for the clinical application of oncolytic viruses.
Authors
- Diancheng Hang
- Hongmei Liu (ORCID: https://orcid.org/0000-0003-1064-2448)
- Jian Gao (ORCID: https://orcid.org/0000-0002-0446-7471)
- Yang Liu (ORCID: https://orcid.org/0000-0003-3260-3896)
- Xuefeng Zhang (ORCID: https://orcid.org/0000-0002-5030-2766)
- Yufu Zhu
- Xiaoqian Wang (ORCID: https://orcid.org/0000-0002-3144-8903)
- Lin Fang (ORCID: https://orcid.org/0000-0003-2418-3617)
- Jiaqi Jin (ORCID: https://orcid.org/0009-0000-0510-4472)
- Hengzhu Zhang (ORCID: https://orcid.org/0000-0003-3240-5689)
Institutions
- Xuzhou Medical College (CN)
- Southern University of Science and Technology (CN)
- First Hospital of China Medical University (CN)
- Yangzhou University (CN)
- China Medical University (CN)
Publication Details
- Journal
- Experimental Hematology and Oncology
- Published
- 2025-02-15
- DOI
- https://doi.org/10.1186/s40164-025-00611-0
- Citations
- 5
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 9.09
Funders
- Science, Technology and Innovation Commission of Shenzhen Municipality
- Shenzhen Fundamental Research Program